Accelerated Phase Chronic Myelogenous Leukemia (CML)

DBCOND0121922Bone Marrow Diseases Hematologic Neoplasms

Accelerated Phase Chronic Myelogenous Leukemia (CML) is the indication for 5 drugs in DrugBank. It is covered by 7 curated, structured indications.

Also known as: Leukemia, Myeloid, Accelerated Phase · Accelerated phase chronic myologenic leukemia · Accelerated Phase Chronic Myelogenous Leukemia · Myelogenous Leukemia, Chronic, Aggressive Phase · Leukemia, Myeloid, Accelerated-Phase
Classified under: Bone Marrow Diseases
Hematologic Neoplasms
Hemic and Lymphatic Disease, Unclassified
Indicated drugs: Bosutinib
Dasatinib
Imatinib
Nilotinib
Ponatinib

Resolves to

Vocabularies

MeSHM0023822ICD-10C92.1SNOMED CT1162588009MedDRA10024296UMLSC0023472

What you can answer from here — as of October 04, 2026

5Indicated drugsWith each drug's targets and mechanism

Listed above

7Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

278Clinical trialsPhase, status and sponsor resolved per trial

3Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Accelerated Phase Chronic Myelogenous Leukemia (CML) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account